Dapagliflozin Metformin Extended-Release Tablets 5/1000 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
MFDS item code 202106883 · Approved 2021.10.13
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood glucose control in adult patients with type 2 diabetes. It is more effective when used in conjunction with dietary and exercise therapy. It can also be used in patients with cardiovascular disease or risk factors; however, it is crucial to refer to a healthcare professional in these cases. This medication helps regulate blood sugar by combining dapagliflozin and metformin and supports patients' healthy living.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no history of prior antidiabetic drug therapy in whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no history of prior antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, treatment may be started at their existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Because any change may alter glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted through the kidneys, and renal function is more likely to be reduced in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication is used for the treatment of diabetes and should not be used in patients with impaired kidney function or certain health conditions. In particular, it should not be administered to patients with moderate to severe renal impairment, severe infection or dehydration, heart failure, acute myocardial infarction, sepsis, or type 1 diabetes. Pregnant or breastfeeding women should also avoid this medication, and patients undergoing surgery should discontinue it 48 hours prior to surgery and resume only after confirming normal kidney function. This medication can rarely cause a serious condition known as lactic acidosis, so both patients and healthcare providers should be aware of the symptoms of lactic acidosis, and any symptoms should prompt immediate medical attention. When used in conjunction with other diabetes medications, the risk of hypoglycemia may increase; therefore, dose adjustments may be necessary when combined with insulin or sulfonylureas. Patients with reduced fluid volume or low blood pressure, elderly patients, and those with impaired kidney function should regularly monitor kidney function and blood pressure before and during treatment. This medication may increase the risk of genital infections or urinary tract infections, so immediate treatment should be sought if infection symptoms develop, and patients with a history of recurrent infections should exercise greater caution. A deficiency in vitamin B12 may occur, so regular monitoring of vitamin B12 levels is advised during prolonged use. Excessive alcohol consumption can increase the risk of side effects from this medication, so it is advisable to avoid alcohol while taking it. Regular monitoring of blood glucose control is necessary during treatment, and any sudden changes in symptoms should be discussed with a healthcare provider immediately. Lastly, this medication should not be used in children as its safety and efficacy have not been established, and special caution should be taken when prescribing to the elderly due to the potential for reduced kidney function.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.
Dark pink, oval, biconvex, film-coated tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.